September 8, 2022
Bioxcellerator, located in Medellin, Colombia, treats patients from around the world with its unique, expanded MSC therapy from Wharton’s Jelly. They have been tracking their patients’ outcomes for over a year, and have granted us permission to share the following early and RWE derived insights:
These follow up data are crucial to helping Bioxcellerator better understand their patients’ outcomes, communicate those expected outcomes to new patients, and achieve more predictable outcomes for all. Upcoming insights will include identifying the patient criteria more commonly associated with non-responders, as well as obtaining statistically significant 12 month follow-ups.
To learn more about Bioxcellerator, click here.
March 28, 2023
Statistical Significance and Clinical Relevance are two important concepts in the field of medicine, and particularly in clinical research. Being a bit more specific, statistical significance refers to the likelihood that a result is not due to chance.
March 17, 2023
Real-world evidence (RWE) is valuable not only for regulatory compliance, clinical decision-making and tracking adverse events. It can also drive patient engagement, profitability and professional advancement.
January 27, 2023
In this newsletter, we summarize the work of leading physicians as they develop clinical decision support for common musculoskeletal pathologies. Through the quality improvement and pragmatic studies embedded in their Circles, those clinicians are generating sustained financial and professional value for themselves, and improving patient care, with minimum burden. Moreover, their Circles are often supported by industry.